China as a Biopharmaceutical Powerhouse: Just a Matter of Time - Despite serious obstacles, development marches ahead - BioPharm International

ADVERTISEMENT

China as a Biopharmaceutical Powerhouse: Just a Matter of Time
Despite serious obstacles, development marches ahead


BioPharm International
Volume 20, Issue 12

The SFDA also enacted new regulations on drug oversight, including new regulations covering exhibitions, channels, cold chain transportation, quality, and other measures.

The government also began to crack down on government corruption. China executed the former SFDA head, Zheng Xiaoyu, in July for dereliction of duty and for taking $850,000 in bribes. Another former SFDA drug registration director was sentenced to death for corruption and dereliction of duty, though his sentence was suspended. The SFDA also banned staff from holding shares in pharmaceutical companies, and created a schedule for local drug administrations with commercial ventures to sever ties.

The crackdown extended to industry, as well. In one example, China's health officials investigated a case involving 1,200 instances of illegal medical advertising. Five medical institutions in Anhui Province were closed and the licenses of nine medical institutions were revoked.

The government revoked 353 licenses for therapeutics for various reasons, including quality, and rejected 3,049 applications for new drugs from August 2006 through February 2007. The SFDA also revoked GMP certificates for Guangdong Bioyee Pharmaceutical Co., due to violation of regulations involving its human immunoglobulin products.

China's SFDA also issued new GLP standards. As of January 2007, all new drug safety evaluations must be conducted in GLP-accredited laboratories. Only 23 laboratories in China are GLP certified.

Some companies are clearly rising to the occasion. SinoBiomed Inc.'s 2,500 square-meter recombinant human interferon GMP production plant in Shanghai has its Chinese GMP certification renewed by the SFDA. The generic drugmaker Zhejiang Huahai Pharmaceutical became the first Chinese manufacturer to pass US FDA inspections (the result of a $13 million, 5-year investment in an anti-AIDS drug).

A series of steps also show that Chinese regulators are paying more attention to drug safety. The SFDA suspended sales of three drugs—the Parkinson's drug Permax; methotrexate, used to treat acute leukemia and rheumatoid arthritis; and Novartis's Zelnorm—because of safety concerns. China's adverse drug reaction (ADR) reports reached a new high in 2006, with 369,392 ADR reports in 2006, up from 173,000 in 2005 and 70,050 in 2004. The higher numbers most likely indicate better reporting rather than actual increases.

INCREASED RESPECT FOR IP

In 2006, Pfizer won an intellectual property (IP) lawsuit for Viagra. As a result, two Chinese companies were required to compensate Pfizer $77,000 for infringing Pfizer's trademark. This suggests an increasing commitment in China to protect IP rights. The fact that the Chinese company involved had appealed the initial decision also indicates a newfound respect for rule of law.

SUMMARY

Predicting economic opportunities in China today remains a challenge. As we track trends and market shifts, we see that the bioscience industries remain a critical component of the economy. China is a centrally planned economy, so market forces are not the only guides. As the country balances its domestic programs with a shift toward a more market-based economy, it is difficult to judge accurately how these market opportunities will balance with current healthcare policies, its direction in life science education, and its economic investment programs. However, recent developments point to generally positive trends.

Eric Langer is president of BioPlan Associates, Rockville, MD, 301.921.9074,


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

EMA Warns of Falsified Herceptin Vials
April 16, 2014
Mallinckrodt to Acquire Questcor Pharmaceuticals
April 16, 2014
American CryoStem and Rutgers University File Joint Patent on Stem Cell Platform
April 11, 2014
Center for Biologics Evaluation and Research Relocates
April 11, 2014
PhRMA Report Reveals Growth Trajectories and Policy Factors Affecting Biopharmaceutical Growth
April 11, 2014
Author Guidelines
Source: BioPharm International,
Click here